Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marina Bluma"'
Autor:
Marco Bucci, Marina Bluma, Irina Savitcheva, Nicholas J. Ashton, Konstantinos Chiotis, Anna Matton, Miia Kivipelto, Guglielmo Di Molfetta, Kaj Blennow, Henrik Zetterberg, Agneta Nordberg
Publikováno v:
Translational Psychiatry, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Plasma biomarkers have shown promising performance in research cohorts in discriminating between different stages of Alzheimer’s disease (AD). Studies in clinical populations are necessary to provide insights on the clinical utility of pla
Externí odkaz:
https://doaj.org/article/051f78dad8a744c5a61fb6863963c5d1
Autor:
Igor C. Fontana, Miriam Scarpa, Mona-Lisa Malarte, Filipa M. Rocha, Sira Ausellé-Bosch, Marina Bluma, Marco Bucci, Konstantinos Chiotis, Amit Kumar, Agneta Nordberg
Publikováno v:
Cells, Vol 12, Iss 11, p 1469 (2023)
Reactive astrogliosis is an early event in the continuum of Alzheimer’s disease (AD). Current advances in positron emission tomography (PET) imaging provide ways of assessing reactive astrogliosis in the living brain. In this review, we revisit cli
Externí odkaz:
https://doaj.org/article/96390f2111d248a19a348c57b2550c76
Autor:
Patrick Oeckl, Marina Bluma, Marco Bucci, Steffen Halbgebauer, Konstantinos Chiotis, Anna Sandebring‐Matton, Nicholas J. Ashton, Guglielmo Di Molfetta, Lana Grötschel, Miia Kivipelto, Kaj Blennow, Henrik Zetterberg, Irina Savitcheva, Agneta Nordberg, Markus Otto
Publikováno v:
Alzheimer's and dementia Advance online publication, n/a (2023). doi:10.1002/alz.13046
β-synuclein is an emerging blood biomarker to study synaptic degeneration in Alzheimer´s disease (AD), but its relation to amyloid-β (Αβ) pathology is unclear.We investigated the association of plasma β-synuclein levels with [18F] flutemetamol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb36c8c0053872299a1a380bfa999c
https://pub.dzne.de/record/258184
https://pub.dzne.de/record/258184
Autor:
Ali H. Al-Nuaimi, Marina Blūma, Shaymaa S. Al-Juboori, Chima S. Eke, Emmanuel Jammeh, Lingfen Sun, Emmanuel Ifeachor
Publikováno v:
Brain Sciences, Vol 11, Iss 8, p 1026 (2021)
Biomarkers to detect Alzheimer’s disease (AD) would enable patients to gain access to appropriate services and may facilitate the development of new therapies. Given the large numbers of people affected by AD, there is a need for a low-cost, easy t
Externí odkaz:
https://doaj.org/article/d048ea0a37274bfe9b9e3323de437af4